Placeholder Banner

BIO Applauds House Passage of Food and Drug Administration Reauthorization Act (FDARA)

July 12, 2017

Washington, DC (July 12, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. House of Representatives:

 “The PDUFA reauthorization package passed by the House of Representatives today is an important victory for patients and for the next generation of medical innovation. This legislation ensures that the FDA continues to have the resources necessary to carry out its critical human drug review programs, while advancing important patient-centered policies that will help streamline the clinical trial process – the most time-consuming, complex and expensive step in the drug development process. It also takes important steps to advance patient involvement in drug development and bring patient perspectives more clearly to bear on regulatory decisions.  The reauthorization of the biosimilars user fee program, including steps to improve communication throughout application review, will move the needle on getting more affordable biosimilar products to patients in a timely way, once the IP protection expires for new biologics.

“We applaud the work of the House for making sure that this important legislation remained a priority. We particularly want to recognize Chairman Walden and Ranking Member Pallone for their tireless, bi-partisan leadership in crafting and advancing the Act. We urge the Senate to swiftly consider and pass the Act to ensure the continuity of the FDA’s many critical functions, and so that patients may begin to benefit from the important advances in drug development that the Act will usher in.” 

 

Upcoming BIO Events

BIO World Congress on Industrial Biotechnology

July 23-26, 2017
Montreal, Canada

BIO Investor Forum
October 17-18, 2017
San Francisco, CA


###

Discover More
The White House today hosted world leaders and key public and private sector partners at the second Global COVID-19 Summit, a virtual event. Following the conversation, Dr. Michelle McMurry-Heath, President and CEO of the…
The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:  "For more than thirty years, the…
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…